Equity Overview
Price & Market Data
Price: $0.642
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $285,793,376
Daily Volume: 0
Performance Metrics
1 Week: 1.65%
1 Month: 60.06%
3 Months: 23.46%
6 Months: -1.02%
1 Year: -29.26%
YTD: -7.37%
Details
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors. The company was incorporated in 2003 and is headquartered in London, the United Kingdom.